Morepen Laboratories consolidated Q1 FY26 PAT lower at Rs. 11.40 Cr

Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025

KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr

KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

Cupid Q1 FY26 PAT jumps 82% at Rs. 15 Cr

Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr

IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025

Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr

Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial